CD4^pos^ Th2 cells are characterized by the production of IL-4, IL-5, IL-9, and IL-13 and promote immunity to helminth infections and allergen-induced inflammation ([@bib4]; [@bib17]; [@bib33]; [@bib37]). Emerging studies indicate that the primarily epithelial cell--derived cytokines thymic stromal lymphopoietin (TSLP), IL-25 (IL-17E), and IL-33 are critical in orchestrating distinct modules of the innate immune response that promote Th2 cell--dependent immunity, inflammation and tissue repair ([@bib40]; [@bib54]; [@bib19]; [@bib31]; [@bib46]; [@bib26]; [@bib33]; [@bib37]). For example, previous studies have shown that TSLP can induce Th2 cytokine--mediated inflammation by activating and promoting the accumulation of multiple cell types including DCs, lymphocytes, mast cells, and basophils ([@bib34]; [@bib38]; [@bib1]; [@bib2]; [@bib20]; [@bib39]; [@bib14]; [@bib35]; [@bib54]; [@bib43]).

Recently, four independent laboratories identified previously unrecognized innate immune cell populations that were capable of contributing to Th2 cytokine responses in vivo ([@bib28]; [@bib30]; [@bib36]; [@bib41]). These cell populations, termed natural helper cells (NHCs), nuocytes, innate type 2 helper (Ih2) cells, or multipotent progenitor type 2 (MPP^type2^) cells, were shown to exhibit many similar phenotypic characteristics. For example, all four cell populations were characterized as being lineage negative (Lin^neg^; lacking expression of hematopoietic cell lineage--associated markers for T cells, B cells, macrophages, DCs, NK cells, lymphoid tissue inducer (LTi) cells, neutrophils, mast cells, basophils, and eosinophils) but expressed Sca1 and c-kit ([@bib28]; [@bib30]; [@bib36]; [@bib41]). Furthermore, these cell populations were elicited after helminth infection, were dependent on IL-25 and/or IL-33 signaling pathways, and could promote Th2 cytokine--mediated inflammation and immunity after exposure to *Trichuris muris* or *Nippostrongylus brasiliensis* ([@bib28]; [@bib30]; [@bib36]; [@bib41]). Based on developmental, phenotypic, and functional similarities, NHCs, nuocytes, and Ih2 cells have been collectively categorized as group 2 innate lymphoid cells (ILC2; [@bib46]; [@bib26]; [@bib44]; [@bib45]; [@bib48]; [@bib50]). Work from this laboratory and many others went on to show that ILC2 are present in multiple tissues in both mice and humans and play critical roles in promoting immunity to helminth parasites, allergic inflammation, and the resolution of pulmonary inflammation ([@bib28]; [@bib30]; [@bib36]; [@bib41]; [@bib23]; [@bib25]; [@bib7]; [@bib11]; [@bib18]; [@bib53]).

Although MPP^type2^ cells share some phenotypic and functional characteristics with other ILC2 populations, their discordant expression of T1/ST2 (IL-33R), IL-7Rα, and CD90 (Thy1) and distinct multipotent potential suggest that MPP^type2^ cells may differ from ILC2 family members. In this study, we use genetic approaches, genome-wide transcriptional profiling, and in vitro and in vivo functional assays to demonstrate that IL-25 simultaneously elicits phenotypically, functionally, and developmentally distinct populations of lymphoid-derived ILC2 and nonlymphoid MPP^type2^ cells. Critically, IL-25--induced MPP^type2^ cells could promote Th2 cytokine--associated inflammation even when ILC2 populations were depleted. These findings indicate that IL-25--elicited MPP^type2^ cells are distinct from ILC2 and suggest that IL-25 simultaneously elicits both lymphoid- and nonlymphoid-associated innate immune cell populations that can promote type 2 inflammation at barrier surfaces.

RESULTS
=======

IL-33 and IL-25 differentially regulate ILC2 and MPP^type2^ cell responses
--------------------------------------------------------------------------

IL-33 and IL-25 were recently shown to elicit previously unrecognized innate immune cell populations that contribute to Th2 cytokine--associated inflammation. These cells express c-kit and Sca1 and were termed NHCs, nuocytes, or Ih2 cells ([@bib28]; [@bib30]; [@bib36]). In addition, a fourth previously unrecognized IL-25--responsive innate cell population has been described, termed MPP^type2^ cells, given their capacity to exhibit multipotent potential to yield macrophages, mast cells, and basophils that can promote Th2 cytokine--mediated immunity ([@bib41]). The identification of multiple IL-25-- or IL-33--responsive innate immune cell populations provokes the question of whether these are four different cell populations or the same cell population identified by four different groups. To directly test whether IL-25 or IL-33 elicits similar or distinct innate cell populations, WT mice were treated with exogenous IL-33 or IL-25 and Lin^neg^ cells in the mesenteric LNs (MLNs) were analyzed for expression of surface markers that define ILC2 versus MPP^type2^ cells (T1/ST2, IL-7Rα, Sca1, CD90, CD25, and c-kit). As previously reported ([@bib30]), administration of recombinant IL-33 elicited increased frequencies of Lin^neg^ T1/ST2^pos^ IL-7Rα^pos^ cells in the MLN ([Fig. 1 a](#fig1){ref-type="fig"}), which express CD90, CD25, and Sca1 ([Fig. 1 b](#fig1){ref-type="fig"} and not depicted), a phenotype consistent with ILC2. In addition, IL-33 treatment resulted in increased total numbers of ILC2 in the MLN ([Fig. 1 c](#fig1){ref-type="fig"}).

![**IL-25 simultaneously elicits phenotypically distinct populations of MPP^type2^ cells and ILC2.** (a--r) C57BL/6 WT mice (The Jackson Laboratory) were treated i.p. with PBS (control), 0.3 µg of recombinant IL-33, or 0.3 µg of recombinant IL-25 daily for 2, 4, or 7 d. Indicated tissues were harvested at day 7 (or as indicated), and the frequency and total cell numbers of ILC2 and MPP^type2^ cells were assessed by flow cytometry. (a) Frequency of T1/ST2^pos^ IL-7Rα^pos^ ILC2 in the Lin^neg^ cell compartment from the MLNs of control or IL-33--treated mice. (b) CD90.2 (Thy1.2) and CD25 expression on ILC2 (black histograms) from IL-33--treated mice. (c) Total cell numbers of ILC2 from control or IL-33--treated mice. (d) Expression of c-kit on gated T1/ST2^neg^ IL-7Rα^neg^ cells from control or IL-33--treated mice. (e) CD90 and CD25 expression on c-kit^pos^ MPP^type2^ cells (black histograms) from IL-33--treated mice. (f) Total cell numbers of MPP^type2^ cells from control or IL-33--treated mice. (g) Frequency of ILC2 in the Lin^neg^ cell compartment from the MLN of control or IL-25--treated mice. (h) CD90 and CD25 expression on ILC2 (black histograms) from IL-25--treated mice. (i) Total cell numbers of ILC2 from control or IL-25--treated mice. (j) Expression of c-kit on gated T1/ST2^neg^ IL-7Rα^neg^ cells from control or IL-25--treated mice. (k) CD90 and CD25 expression on c-kit^pos^ MPP^type2^ cells (black histograms) from IL-25--treated mice. (l) Total cell numbers of MPP^type2^ cells from control or IL-25--treated mice. Plots are gated on live, Lin^neg^ (CD4, CD8, CD11b, CD11c, and CD19) cells or as indicated. Gray shaded histograms represent CD90 or CD25 expression on Lin^neg^ cells from control mice. (m and n) Frequencies of ILC2 (m) or MPP^type2^ cells (n) as gated in a, g, d, and i from the MLNs of control (open bars), IL-33--treated, or IL-25--treated mice at days 2, 4, and 6. (o--r) Frequencies of ILC2 and MPP^type2^ cells as gated in a and g and d and i from the blood (o), caudal LN (p), lung (q), and PEC (r) of control (open bars), IL-33--treated (black bars), or IL-25--treated (gray bars) mice at day 6. Data in a--n are representative of two or more independent experiments (control, *n* = 4; IL-33 treated, *n* = 8; IL-25 treated, *n* = 8). Data in o--r are representative of two independent experiments (control, *n* = 4; IL-25 treated, *n* = 8; IL-33 treated, *n* = 8). \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.0001. Lung IL-33--elicited ILC2 versus IL-25--elicited ILC2, P = 0.07; PEC IL-33--elicited MPP^type2^ cells versus IL-25--elicited MPP^type2^ cells, P = 0.31. Error bars indicate SEM.](JEM_20122332_Fig1){#fig1}

Although IL-33--mediated induction of ILC2 populations is well characterized ([@bib5]; [@bib30]), whether IL-33 also elicits MPP^type2^ cells remains unclear. To test this, the frequency and number of Lin^neg^ T1/ST2^neg^ IL-7Rα^neg^ cells that express c-kit were analyzed. Compared with controls, IL-33--treated mice exhibited modest increases in the frequencies ([Fig. 1 d](#fig1){ref-type="fig"}) and total numbers ([Fig. 1 f](#fig1){ref-type="fig"}) of Lin^neg^ T1/ST2^neg^ IL-7Rα^neg^ c-kit^pos^ cells, which was independent of IL-25 (not depicted). In addition, these cells expressed Sca1 (not depicted) but lacked expression of CD90 and CD25 ([Fig. 1 e](#fig1){ref-type="fig"}), a phenotype consistent with that of MPP^type2^ cells but distinct from Lin^neg^ T1/ST2^pos^ IL-7Rα^pos^ ILC2 cells.

Previous studies demonstrated redundancy between IL-33 and IL-25 to induce ILC2 populations but have also shown that treatment with exogenous IL-33 elicits a more robust ILC2 response in the lung than IL-25 ([@bib30]; [@bib5]). Therefore, to address whether IL-25 elicits similar innate immune cell populations and with a similar magnitude to IL-33, WT mice were treated with exogenous IL-25 at the same time as mice that were treated with IL-33 as depicted above, and the frequency of ILC2 and MPP^type2^ cells were assessed. IL-25 treatment was associated with modest increases in the frequencies ([Fig. 1 g](#fig1){ref-type="fig"}) and total numbers of ILC2 populations in the MLN ([Fig. 1 i](#fig1){ref-type="fig"}), which displayed heterogeneous expression of CD90 and CD25 ([Fig. 1 h](#fig1){ref-type="fig"}). In contrast to eliciting modest ILC2 responses, administration of IL-25 elicited increased frequencies ([Fig. 1, j and k](#fig1){ref-type="fig"}) and significantly elevated total numbers of Lin^neg^ c-kit^pos^ MPP^type2^ cells in the MLN ([Fig. 1 l](#fig1){ref-type="fig"}).

Increased frequencies of ILC2 were observed as early as 2 d after IL-33 treatment and continued to increase at days 4 and 6 ([Fig. 1 m](#fig1){ref-type="fig"}, black bars). In contrast, the IL-25--mediated induction of ILC2 was not apparent until days 4--6 ([Fig. 1 m](#fig1){ref-type="fig"}, gray bars) and remained modest in comparison with IL-33--elicited ILC2 responses. In addition, although administration of IL-33 resulted in an early (day 2) modest increase in the frequency of T1/ST2^neg^ IL-7Rα^neg^ c-kit^pos^ MPP^type2^ cells in the MLN, the frequency did not increase at days 4 or 6 ([Fig. 1 n](#fig1){ref-type="fig"}, black bars). However, induction of MPP^type2^ cells after IL-25 treatment was observed as early as day 2 after treatment and continued to increase through day 6 ([Fig. 1 n](#fig1){ref-type="fig"}, gray bars). Moreover, the selectivity of IL-33--elicited ILC2 and IL-25--elicited MPP^type2^ cells was observed in multiple anatomical sites including the blood ([Fig. 1 o](#fig1){ref-type="fig"}), caudal LN ([Fig. 1 p](#fig1){ref-type="fig"}), lung ([Fig. 1 q](#fig1){ref-type="fig"}), and peritoneal cavity (PEC; [Fig. 1 r](#fig1){ref-type="fig"}). Collectively, these data indicate that IL-33 predominantly elicits ILC2 responses with limited effects on MPP^type2^ cells, whereas IL-25 robustly promotes MPP^type2^ cell responses in multiple anatomical sites.

IL-25 elicits MPP^type2^ cells independently of IL-33--IL-33R interactions
--------------------------------------------------------------------------

IL-33 and IL-25 were shown to redundantly elicit ILC2 ([@bib30]). To test whether IL-25 can promote the induction of ILC2 or MPP^type2^ cells independently of IL-33--IL-33R interactions, WT and *Il33^−/−^* mice were treated with IL-25 and ILC2, and MPP^type2^ cell responses were assessed. IL-25--treated WT mice displayed a modest increase in the frequency and total cell number of ILC2 cells in the MLN compared with control mice ([Fig. 2, a and b](#fig2){ref-type="fig"}). Furthermore, IL-33--deficient mice treated with IL-25 exhibited a similar increase in the frequencies and total cell numbers of ILC2 cells to those observed in WT mice ([Fig. 2, c and d](#fig2){ref-type="fig"}). Critically, IL-25 treatment also resulted in increased frequencies and total cell numbers of MPP^type2^ cells in both WT ([Fig. 2, e and f](#fig2){ref-type="fig"}) and IL-33--deficient mice ([Fig. 2, g and h](#fig2){ref-type="fig"}). Similarly, mice treated with IL-25 in the presence of a neutralizing mAb against the IL-33 receptor (T1/ST2) exhibited increased frequencies and total cell numbers of MPP^type2^ cells at levels comparable with those observed in mice treated with IL-25 and an isotype control mAb ([Fig. 2, i--l](#fig2){ref-type="fig"}). Collectively, these data indicate that IL-25 simultaneously elicits distinct ILC2 and MPP^type2^ cell populations in IL-33--sufficient and --deficient environments.

![**IL-25 elicits ILC2 and MPP^type2^ cells independent of IL-33 signaling.** (a--d) C57BL/6 WT mice and C57BL/6 *Il33^−/−^* mice (Taconic) were treated i.p. with PBS (control) or 0.3 µg of recombinant IL-25 daily for 7 d. MLNs were harvested at day 7, and the frequency and total cell numbers of ILC2 and MPP^type2^ cells were assessed by flow cytometry. (a and c) Frequency of ILC2 in control or IL-25--treated WT (a) or *Il33^−/−^* mice (c). (b and d) Total cell numbers of ILC2 in control or IL-25--treated WT (b) or *Il33^−/−^* mice (d). (e and g) Frequency of MPP^type2^ cells in control or IL-25--treated WT (e) or *Il33^−/−^* mice (g). (f and h) Total cell numbers of MPP^type2^ cells in control or IL-25--treated WT (f) or *Il33^−/−^* mice (h). Data in a--h are representative of two independent experiments (control, *n* = 4; IL-25--treated WT, *n* = 6; IL-25--treated *Il33^−/−^*, *n* = 6). (i--l) BALB/c WT mice (The Jackson Laboratory) were treated with PBS (control) or 0.3 µg of recombinant IL-25 plus isotype (IgG) or anti-T1/ST2 mAbs. MLNs were harvested at day 7, and the frequency and total cell numbers of ILC2 and MPP^type2^ cells were assessed by flow cytometry. Frequency and total numbers of T1/ST2^pos^ IL-7Rα^pos^ ILC2 (i and j) and T1/ST2^neg^ IL-7Rα^neg^ c-kit^pos^ MPP^type2^ cells (k and l). Plots are gated on live, Lin^neg^ (CD4, CD8α, CD11b, CD11c, and CD19) cells. Data in i--l are representative of two independent experiments (control, *n* = 6; IL-25 treated, *n* = 9; anti-T1/ST2 IL-25 treated, *n* = 9). Error bars indicate SEM.](JEM_20122332R_Fig2){#fig2}

MPP^type2^ cells exhibit distinct transcriptional profiles from ILCs
--------------------------------------------------------------------

The capacity of IL-25 to elicit MPP^type2^ cells independently of IL-33--IL-33R signaling and the finding that MPP^type2^ cells possess a distinct surface phenotype from ILC2 provoked the hypothesis that MPP^type2^ cells may be distinct from ILC2. To investigate potential differences between MPP^type2^ cells and ILC2, genome-wide transcriptional profiling was performed. IL-25--elicited MPP^type2^ cells (defined as Lin^neg^ T1/ST2^neg^ IL-7Rα^neg^ CD90^neg^ CD25^neg^ c-kit^pos^) were sort-purified to a purity of ≥95% ([Fig. 3, a and b](#fig3){ref-type="fig"}), mRNA was hybridized onto microarray chips, and the transcriptional profile of MPP^type2^ cells was compared against the transcriptional profile of Lin^neg^ T1/ST2^pos^ IL-7Rα^pos^ CD90^pos^ CD25^pos^ lung-resident ILC2 ([@bib25]). Examination of the top 100 most differentially expressed genes between MPP^type2^ cells and lung-resident ILC2 revealed substantial differences between these two populations ([Fig. 3 c](#fig3){ref-type="fig"}). Consistent with previous studies ([@bib30]; [@bib25]), ILC2 cells were characterized by expression of genes encoding T1/ST2 (*Il1rl1*), the cytokines IL-2 (*Il2*) and IL-5 (*Il5*), and the wound-healing response protein amphiregulin (*Areg*; [Fig. 3 c](#fig3){ref-type="fig"}). In contrast, MPP^type2^ cells were enriched for genes encoding innate immune signaling pathways (Klr and C1q proteins), hematopoietic stem cell (HSC)--associated genes (*Pf4*), and myeloid-associated genes (*Itgam* and *Cd74*; [Fig. 3 c](#fig3){ref-type="fig"}).

![**IL-25--elicited MPP^type2^ cells possess a unique transcriptional profile from ILC2 cells.** (a and b) C57BL/6 WT mice (The Jackson Laboratory) were treated with 0.3 µg of recombinant IL-25 daily for 7 d. MLNs and PECs were harvested from IL-25--treated mice and MPP^type2^ cells (Lin^neg^ T1/ST2^neg^ IL-7Rα^neg^ CD4^neg^ CD90^neg^ CD25^neg^ c-kit^pos^; a) were FACS purified to ≥95% purity (b). Three biological replicates of MPP^type2^ cells were collected, and mRNA was isolated, amplified, and hybridized to Affymetrix gene chips for microarray analysis. The previously published microarray gene expression profile of lung-resident ILC2 was used for comparison (GEO series no. [GSE46468](GSE46468); [@bib25]). (c) Heat map representing gene expression profiles of the top 100 differentially expressed genes between MPP^type2^ cells and ILC2. Red indicates high expression, and blue indicates low expression. (d) GSEA comparing the gene expression signatures of MPP^type2^ cells and ILC2. (e) List of leading edge genes from GSEA analysis from d. (f) PCA plot comparing transcriptional profiles for MPP^type2^ cells (1), ex vivo nuocytes (2; [GSE25890](GSE25890)), NHCs (3; [GSE18752](GSE18752)), lung-resident ILC2 (4; [GSE46468](GSE46468)), unstimulated lung NHCs (5; [GSE36057](GSE36057)), splenic LTi cells (6, [GSE46468](GSE46468); and 7, [GSE18752](GSE18752)), and BM-GMPs (8). Categories of ILC2 (green shaded area), ILC3 (red shaded area), and progenitors (blue shaded area) were grouped (as indicated in f, dashed lines), and Euclidean distance measurements between MPP^type2^ cells and BM-GMP versus ILC2 or ILC3 were calculated (g). \*\*\*, P \< 0.0001. MPP^type2^ cells versus BM-GMP versus ILC2, P = 8.5 × 10^−8^; MPP^type2^ cells versus BM-GMP versus ILC3s, P = 3.1 × 10^−6^.](JEM_20122332_Fig3){#fig3}

To further assess the differences in transcriptional profiles between MPP^type2^ and ILC2 cells, gene set enrichment analysis (GSEA) was performed ([@bib47]). GSEA demonstrated that lung-resident ILC2 cells were enriched for gene expression associated with epidermal growth factor (EGF) signaling, cytokine--receptor interactions, nuclear receptor transcription, and inflammatory pathways ([Fig. 3, d and e](#fig3){ref-type="fig"}). In contrast, IL-25--elicited MPP^type2^ cells exhibited a gene expression profile enriched for HSCs, antigen processing/presentation, lysosomal proteins, and innate immune signaling pathways ([Fig. 3, d and e](#fig3){ref-type="fig"}), a finding consistent with the potential of MPP^type2^ cells to differentiate into macrophage and granulocyte populations.

In addition, to assess the differences in transcriptional profiles between MPP^type2^ cells and ILC2 populations, we undertook a more comprehensive characterization of the genome-wide transcriptional profiles for MPP^type2^ cells ([Fig. 3 f](#fig3){ref-type="fig"}, 1) and compared them against microarray datasets for ILC2 generated by multiple laboratories (including nuocytes \[2\], NHCs \[3\], lung-resident ILC2 \[4\], and lung NHCs \[5\]; [@bib28]; [@bib30]; [@bib25]; [@bib10]). In addition, ILC3 microarray datasets were included from multiple laboratories ([Fig. 3 f](#fig3){ref-type="fig"}, 6 and 7, LTi-like cells; [@bib25] and [@bib28], respectively) as a comparison to a known population of distinct innate immune cells ([Fig. 3 f](#fig3){ref-type="fig"}). Finally, given the phenotypic and genome-wide transcriptional profile of the IL-25--elicited MPP^type2^ cells ([Fig. 3, c--e](#fig3){ref-type="fig"}), a BM-resident granulocyte/monocyte precursor (BM-GMP) cell population was also included ([Fig. 3 f](#fig3){ref-type="fig"}, 8) in these unbiased analyses of transcriptional profiles.

Principal component analysis (PCA) was performed using batch-corrected microarray datasets from ILC2, ILC3, MPP^type2^, and BM-GMP cells to generate a plot of the first two components that accounted for ∼40% of the total variance between all groups ([Fig. 3 f](#fig3){ref-type="fig"}). As expected, ILC3 populations clustered together ([Fig. 3 f](#fig3){ref-type="fig"}). Notably, although nuocytes did not cluster as closely with other ILC2 populations, as expected based on surface marker phenotype and function, ILC2 reported by multiple groups (NHCs, lung-resident ILC2, and lung NHCs) clustered tightly together ([Fig. 3 f](#fig3){ref-type="fig"}, green shaded area) and did not cluster with ILC3 ([Fig. 3 f](#fig3){ref-type="fig"}, red shaded area). Critically, however, IL-25--elicited MPP^type2^ cells ([Fig. 3 f](#fig3){ref-type="fig"}, 1) did not cluster with either ILC2 or ILC3, but instead clustered with BM-GMP ([Fig. 3 f](#fig3){ref-type="fig"}), suggesting that MPP^type2^ cells represent a distinct innate cell population from ILC2 and ILC3. Analysis of the Euclidean distances between MPP^type2^ cells and BM-GMP ([Fig. 3, f and g](#fig3){ref-type="fig"}, blue shaded area) showed that they were significantly shorter than the distances between MPP^type2^ cells and ILC2 ([Fig. 3, f and g](#fig3){ref-type="fig"}, green shaded area) or ILC3 ([Fig. 3, f and g](#fig3){ref-type="fig"}, red shaded area), indicating that MPP^type2^ cells are more similar to BM-GMP than to ILC2 or ILC3. Together, these data suggest that MPP^type2^ cells exhibit a transcriptional profile similar to that of BM-derived hematopoietic progenitor populations and are thus distinct from known ILC populations.

MPP^type2^ cells, but not ILC2, exhibit progenitor potential
------------------------------------------------------------

The transcriptional profiles coupled with clustering analyses of MPP^type2^ cells suggested that MPP^type2^ cells might represent a progenitor cell population capable of differentiating into multiple cell lineages, in agreement with previously reported findings ([@bib41]). To test whether ILC2 and MPP^type2^ cells exhibit similar progenitor cell capacities, cells were sort-purified from IL-25--treated mice and cultured in the presence of IL-33 alone or SCF and IL-3. The resultant progeny were analyzed for differentiation into multiple cell lineages by flow cytometry based on surface marker expression. Consistent with previous studies ([@bib28]; [@bib30]), analysis of FACS-purified ILC2 ([Fig. 4 a](#fig4){ref-type="fig"}) cultured in the presence of IL-33 revealed that ILC2 proliferated but did not differentiate into macrophages or mast cells ([Fig. 4 b](#fig4){ref-type="fig"} and not depicted). However, IL-33--stimulated ILC2 retained their T1/ST2 expression ([Fig. 4 b](#fig4){ref-type="fig"}) and produced elevated levels of IL-5 and IL-13 but little IL-4 ([Fig. 4 g](#fig4){ref-type="fig"}). In addition, ILC2 cultured in the presence of SCF and IL-3 did not differentiate into macrophages or mast cells, but a small proportion of the cells retained their ILC2 surface phenotype ([Fig. 4 c](#fig4){ref-type="fig"}), indicating that ILC2 cells are a terminally differentiated cell population unable to give rise to other cell lineages.

![**IL-25--elicited MPP^type2^ cells, but not ILC2, possess multipotent potential.** BALB/c WT mice (The Jackson Laboratory) were treated with 0.3 µg of recombinant IL-25 daily for 7 d. MLNs and PECs were harvested from IL-25--treated mice, and ILC2 and MPP^type2^ cells were sort-purified and cultured in the presence of IL-33 alone or SCF plus IL-3. (a and d) FACS purification gating of ILC2 (Lin^neg^ T1/ST2^pos^ IL-7Rα^pos^; a) or MPP^type2^ cells (Lin^neg^ T1/ST2^neg^ IL-7Rα^neg^ c-kit^pos^; d) from IL-25--treated mice. Plots shown are gated on live, Lin^neg^ cells (CD3*ε*, CD8α, CD19, CD11b, CD11c, Gr-1). (b and c) Flow cytometric analysis of myeloid, granulocyte, and ILC2 cell differentiation of day 8--12 cultures seeded with FACS-purified ILC2 in the presence of IL-33 (b) or SCF and IL-3 (c). (e and f) Flow cytometric analysis of macrophage, granulocyte, and ILC2 cell differentiation of day 8--12 cultures seeded with FACS-purified MPP^type2^ cells in the presence of IL-33 (e) or SCF and IL-3 (f). (g) Culture supernatants from b, c, e, and f were collected, and IL-4, IL-5, and IL-13 protein levels were measured by ELISA. Data in a--g are representative of at least three independent experiments. Error bars indicate SEM.](JEM_20122332_Fig4){#fig4}

In contrast to ILC2, when cultured in the presence of IL-33 alone, FACS-purified MPP^type2^ cells ([Fig. 4 d](#fig4){ref-type="fig"}) yielded a small but identifiable CD11b^pos^ macrophage-like cell population but did not give rise to a CD11b^neg^ c-kit^pos^ Fc*ε*RI^pos^ mast cell population or a CD11b^neg^ T1/ST2^pos^ ILC2 population ([Fig. 4 e](#fig4){ref-type="fig"}). Furthermore, after culture with IL-33, MPP^type2^ cells and their progeny did not produce IL-4, IL-5, or IL-13 ([Fig. 4 g](#fig4){ref-type="fig"}), indicating that MPP^type2^ cells do not differentiate and produce cytokines in response to IL-33. However, in vitro cultures seeded with MPP^type2^ cells in the presence of SCF and IL-3 contained substantial frequencies of CD11b^pos^ macrophages as well as CD11b^neg^ c-kit^pos^ Fc*ε*RI^pos^ mast cells but did not contain T1/ST2^pos^ IL-7Rα^pos^ ILC2 ([Fig. 4 f](#fig4){ref-type="fig"}). Critically, in contrast to IL-25--elicited ILC2, progeny derived from IL-25--elicited MPP^type2^ cells produced elevated levels of IL-4 but not IL-5 or IL-13 ([Fig. 4 g](#fig4){ref-type="fig"}). Combined with the differences observed in surface phenotype, transcriptional profile and the finding that MPP^type2^ cells but not ILC2 possess multipotent potential, these data support the hypothesis that MPP^type2^ cells are distinct from ILC2.

Consistent with a degree of redundancy between IL-33 and IL-25, IL-33 also elicited modest increases in the frequencies of MPP^type2^-like cells ([Fig. 1, d--f](#fig1){ref-type="fig"}). Therefore, to investigate whether IL-33--elicited ILC2 and MPP^type2^ cells display similar functional potential compared with the IL-25--elicited cell populations, we sort-purified ILC2 or MPP^type2^ cell populations from the MLNs of IL-33--treated mice ([Fig. 5, a and d](#fig5){ref-type="fig"}) and cultured them in the presence of IL-33 alone or SCF and IL-3. After culture, resultant progeny were assessed for differentiation into myeloid, granulocyte, or ILC2 lineages ([Fig. 5, b, c, e, and f](#fig5){ref-type="fig"}). Consistent with IL-25--elicited ILC2, IL-33--elicited ILC2 proliferated and retained their expression of T1/ST2 in response to IL-33 ([Fig. 5 b](#fig5){ref-type="fig"}). However, when cultured in the presence of SCF and IL-3, ILC2 from IL-33--treated mice did not differentiate into macrophages, mast cells, or basophils but did retain an ILC2 surface phenotype ([Fig. 5 c](#fig5){ref-type="fig"}), suggesting that consistent with the phenotype of IL-25--induced ILC2 and previously published data, IL-33--elicited ILC2 are a terminally differentiated cell population and cannot develop into myeloid lineages ([@bib28]).

![**IL-33--elicited MPP^type2^ cells, but not ILC2, possess multipotent potential.** BALB/c WT mice (The Jackson Laboratory) were treated with 0.3 µg of recombinant IL-33 daily for 7 d. MLNs and PECs were harvested from IL-33--treated mice, and ILC2 and MPP^type2^ cells were sort-purified and cultured in the presence of IL-33 alone or SCF plus IL-3. (a and d) FACS purification gating of ILC2 (Lin^neg^ T1/ST2^pos^ IL-7Rα^pos^; a) or MPP^type2^ cells (Lin^neg^ T1/ST2^neg^ IL-7Rα^neg^ c-kit^pos^; d) from IL-33--treated mice. Plots shown are gated on live, Lin^neg^ cells (CD3*ε*, CD8α, CD19, CD11b, CD11c, and Gr-1). (b and c) Flow cytometric analysis of myeloid, granulocyte, and ILC2 cell differentiation of day 8--12 cultures seeded with FACS-purified ILC2 in the presence of IL-33 (b) or SCF and IL-3 (c). (e and f) Flow cytometric analysis of myeloid, granulocyte, and ILC2 cell differentiation of day 8 cultures seeded with FACS-purified MPP^type2^ cells in the presence of IL-33 (e) or SCF and IL-3 (f). Data in a--f are representative of at least two independent experiments.](JEM_20122332_Fig5){#fig5}

Similar to IL-25--elicited MPP^type2^ cells, when cultured in the presence of IL-33 alone, MPP^type2^ cells from IL-33--treated mice did not give rise to substantial populations of macrophages, mast cells, or ILC2 ([Fig. 5 e](#fig5){ref-type="fig"}). However, when cultured in the presence of SCF and IL-3, IL-33--elicited MPP^type2^ cells yielded CD11b^pos^ macrophages and CD11b^neg^ c-kit^pos^ Fc*ε*RI^pos^ mast cells but not ILC2 ([Fig. 5 f](#fig5){ref-type="fig"}). Combined, these data suggest that IL-33--elicited ILC2 and MPP^type2^ cells respond to IL-33 or SCF + IL-3 in a similar fashion to their IL-25--elicited counterparts and further demonstrate that, in contrast to ILC2, MPP^type2^ cells uniquely exhibit multipotent potential.

MPP^type2^ cell responses are partially independent of Id2
----------------------------------------------------------

ILC2 are developmentally dependent on the lymphoid lineage specifying transcription factor inhibitor of DNA binding 2 (Id2; [@bib28]; [@bib25]). Therefore, to test whether MPP^type2^ cell responses could be induced in the absence of Id2, BM chimeras were generated in which either WT or Id2-deficient BM cells were transplanted into lethally irradiated congenic WT recipients. 8 wk after transplantation, chimeric mice were treated daily with either IL-33 or IL-25 for 7 d, and the induction of ILC2 populations and MPP^type2^ cells was evaluated. Congenic mice that received WT BM exhibited increased frequencies and total cell numbers of donor-derived ILC2 cells in the MLN after treatment with IL-33 ([Fig. 6, a and b](#fig6){ref-type="fig"}). Consistent with the developmental dependence of ILC2 cells on Id2, administration of IL-33 failed to induce donor-derived ILC2 cells in mice that received *Id2^−/−^* BM ([Fig. 6, c and d](#fig6){ref-type="fig"}). In contrast, IL-33 elicited donor-derived MPP^type2^ cells in both WT and Id2-deficient chimeras ([Fig. 6, e--h](#fig6){ref-type="fig"}), suggesting that MPP^type2^ cells do not require Id2 for their development.

![**IL-25--mediated induction of MPP^type2^ cells occurs independently of Id2.** (a--p) CD5/B220-depleted donor BM (WT, CD45.1; *Id2^−/−^*, CD45.1.2) was transferred into lethally irradiated C57BL/6 WT (CD45.2) mice. After reconstitution for 8 wk after transplant, mice were treated i.p. with PBS (control), 0.3 µg of recombinant IL-33, or 0.3 µg of recombinant IL-25 daily for 7 d. MLNs were harvested, and the frequency and total cell numbers of ILC2 and MPP^type2^ cells were assessed by flow cytometry. (a and c) Frequency of T1/ST2^pos^ IL-7Rα^pos^ ILC2 from control or IL-33--treated WT BM chimera mice (a) or Id2-deficient BM chimera mice (c). (b and d) Total cell numbers of ILC2 from control or IL-33--treated WT BM chimera mice (b) or Id2-deficient BM chimera mice (d). (e and g) Frequency of c-kit^pos^ MPP^type2^ cells from control or IL-33--treated WT BM chimera mice (e) or Id2-deficient BM chimera mice (g). (f and h) Total cell numbers of MPP^type2^ cells from control or IL-33--treated WT BM chimera mice (f) or Id2-deficient BM chimera mice (h). (i and k) Frequency of T1/ST2^pos^ IL-7Rα^pos^ ILC2 cells from control or IL-25--treated WT BM chimera mice (i) or Id2-deficient BM chimera mice (k). (j and l) Total cell numbers of ILC2 from control or IL-25--treated WT BM chimera mice (j) or Id2-deficient BM chimera mice (l). (m and o) Frequency of c-kit^pos^ MPP^type2^ cells from control or IL-25--treated WT BM chimera mice (m) or Id2-deficient BM chimera mice (o). (n and p) Total cell numbers of MPP^type2^ cells from control or IL-25--treated WT BM chimera mice (n) or Id2-deficient BM chimera mice (p). Plots are gated on live, Lin^neg^ (CD4, CD8, CD11b, CD11c, and CD19) donor-derived cells. Data in a--p are representative of two or more independent experiments (control, *n* = 4; IL-33 treated, *n* = 6; IL-25 treated, *n* = 6). Error bars indicate SEM.](JEM_20122332_Fig6){#fig6}

IL-25 induced the modest increase in the frequency and total cell numbers of donor-derived ILC2 in WT chimeras ([Fig. 6, i and j](#fig6){ref-type="fig"}) but did not elicit an ILC2 population from Id2-deficient donor cells ([Fig. 6, k and l](#fig6){ref-type="fig"}). Administration of IL-25 also resulted in increased frequencies and total cell numbers of donor-derived MPP^type2^ cells in mice that received WT BM ([Fig. 6, m and n](#fig6){ref-type="fig"}). Furthermore, although diminished compared with the induction observed in WT mice (27% compared with 77%), treatment of *Id2^−/−^* BM chimeras with IL-25 resulted in the population expansion and increased total cell numbers of MPP^type2^ cells from donor-derived cells ([Fig. 6, o and p](#fig6){ref-type="fig"}). Thus, in contrast to ILC2, which are critically dependent on Id2 for their development, administration of IL-25 could partially promote MPP^type2^ cell responses in both the presence and absence of Id2, supporting the hypothesis that IL-25 elicits two developmentally distinct innate immune cell populations, ILC2 and MPP^type2^ cells.

MPP^type2^ cells can promote type 2 inflammation in the absence of ILC2
-----------------------------------------------------------------------

To investigate the innate immune mechanisms through which IL-25 and IL-33 promote type 2 inflammation, the function of MPP^type2^ cells was assessed in vivo in mice depleted of ILC2. Using the anti-CD90 mAb--mediated depletion protocol in *Rag1^−/−^* mice, ILCs can be depleted in vivo without influencing the frequencies of MPP^type2^ cells ([Fig. 7](#fig7){ref-type="fig"}), which do not express CD90 ([Fig. 1 k](#fig1){ref-type="fig"}). *Rag1^−/−^* mice were treated with IL-25 and simultaneously administered either an isotype control antibody or anti-CD90 mAb. After IL-25 treatment, the frequencies of ILC2 and MPP^type2^ cells and Th2 cytokine--associated inflammation were assessed. As expected, compared with control-treated mice, IL-25 treatment induced increased frequencies and total cell numbers of CD90^pos^ T1/ST2^pos^ IL-7Rα^pos^ ILC2 cells ([Fig. 7, a and b](#fig7){ref-type="fig"}) and a c-kit^pos^ MPP^type2^ cell population in the MLN ([Fig. 7, c and d](#fig7){ref-type="fig"}). These responses were associated with increased expression of *Il4*, *Il5*, and *Il13* in the lung and small intestine ([Fig. 7, e and f](#fig7){ref-type="fig"}), goblet cell hyperplasia in the lung and small intestine ([Fig. 7, g and h](#fig7){ref-type="fig"}), and increased frequencies and total cell numbers of eosinophils in the lung ([Fig. 7 i](#fig7){ref-type="fig"}). Treatment with anti-CD90 mAb resulted in the depletion of CD90^pos^ T1/ST2^pos^ IL-7Rα^pos^ ILC2 cells ([Fig. 7, a and b](#fig7){ref-type="fig"}). Critically, despite depletion of ILC2, IL-25--mediated induction of c-kit^pos^ MPP^type2^ cells ([Fig. 7, c and d](#fig7){ref-type="fig"}), induction of *Il4*, *Il5*, and *Il13* expression in the lung and intestine ([Fig. 7, e and f](#fig7){ref-type="fig"}), promotion of goblet cell hyperplasia in the lung and small intestine ([Fig. 7, g and h](#fig7){ref-type="fig"}), and eosinophil responses ([Fig. 7 i](#fig7){ref-type="fig"}) were not affected. Thus, these data indicate that after depletion of ILC2, administration of IL-25 can still promote the induction of MPP^type2^ cells and type 2 inflammation and suggest that IL-25--elicited MPP^type2^ cells can promote Th2 cell--dependent immune responses independent of ILC2.

![**IL-25--mediated induction of MPP^type2^ cells and type 2 inflammation occurs independently of ILC2.** (a--i) C57BL/6 *Rag1^−/−^* mice (The Jackson Laboratory) were treated i.p. with PBS (control) or 0.3 µg of IL-25 plus isotype mAb (Iso.) or anti-CD90 mAb. (a and b) Frequencies (a) and total cell numbers (b) of CD90^pos^ T1/ST2^pos^ IL-7Rα^pos^ ILC2 in the MLNs of control or IL-25--treated mice given either isotype or anti-CD90 mAb. (c and d) Frequencies (c) and total cell numbers (d) of CD90^neg^ T1/ST2^neg^ IL-7Rα^neg^ MPP^type2^ cells in the MLNs of control or IL-25--treated mice given either isotype or anti-CD90 mAb. Plots are gated on live, Lin^neg^ (CD4, CD8, CD11b, CD11c, and CD19) cells or as indicated. (e and f) Quantitative real-time PCR of *Il4*, *Il5*, and *Il13* gene expression levels from lung (e) or small intestinal tissue (f) of control or IL-25--treated mice receiving either isotype or anti-CD90 mAb. RQ, relative quantification. (g) Periodic acid--Schiff/Alcian blue staining of lung and small intestine (SI) tissue from control or IL-25--treated mice receiving either isotype or anti-CD90 mAb. Bars: (top) 50 µm; (bottom) 100 µm. (h) Goblet cell (GC) counts from g. nd, not detected. (i) Frequency and total cell numbers of eosinophils in the lung from control or IL-25--treated mice given either isotype or anti-CD90 mAb. Frequency is percentage of SSC^hi^ SiglecF^pos^ cells gated on live, Lin^neg^ CD11b^pos^ cells. Data in a--i are representative of three independent experiments (control + Iso., *n* = 6; control + anti-CD90, *n* = 6; IL-25 treated + Iso., *n* = 6; IL-25 treated + anti-CD90, *n* = 6). \*, P \< 0.05; \*\*, P \< 0.01. Control ILC2 versus IL-25 + Iso. ILC2, P = 0.057; IL-25 + Iso. ILC2 versus IL-25 + αCD90 ILC2, P = 0.059; IL-25 + Iso. MPP^type2^ versus IL-25 + αCD90 MPP^type2^, P = 0.41; lung GC\#: IL-25 + Iso. versus IL-25 + αCD90, P = 0.10; SI GC\#: IL-25 + Iso. versus IL-25 + αCD90, P = 0.16. Error bars indicate SEM.](JEM_20122332_Fig7){#fig7}

MPP^type2^ cells promote Th2 cytokine responses and protective immunity
-----------------------------------------------------------------------

To test whether MPP^type2^ cells were sufficient to promote Th2 cytokine--associated immune responses in a lymphocyte-sufficient environment, MPP^type2^ cells were FACS purified from IL-25--treated mice and injected intradermally into naive WT C57BL/6 mice. At day 5 after injection, skin-draining LNs were collected and stimulated with αCD3/αCD28, and cytokine production was assessed. After adoptive transfer, cells isolated from the skin-draining LNs of mice that had received MPP^type2^ cells exhibited elevated IL-4 and IL-5 production with only a modest increase in IL-13 protein levels compared with mice that received intradermal injection of PBS alone ([Fig. 8 a](#fig8){ref-type="fig"}), suggesting that MPP^type2^ cells can promote conditions permissive for the development of Th2 cell responses.

![**IL-25--elicited MPP^type2^ cells promote Th2 cytokine--dependent responses in vivo.** C57BL/6 WT mice (The Jackson Laboratory) were treated i.p. with 0.3 µg IL-25 daily for 7 d. MLNs were harvested, and MPP^type2^ cells were sort-purified and injected intradermally into naive C57BL/6 WT mice. (a) IL-4, IL-5, and IL-13 cytokine production from skin-draining LN cells from mice receiving intradermal injection of control or IL-25--elicited MPP^type2^ cells after 48-h αCD3/αCD28 stimulation measured by ELISA. Data in a are representative of two independent experiments. (b--f) C57BL/6 WT mice were treated i.p. with 0.3 µg IL-25 daily for 7 d. MLNs were harvested, and MPP^type2^ cells were sort-purified and injected into *T. muris*--infected (INF) *Il17rb^−/−^* mice (Charles River). (b) IFN-γ cytokine production by *T. muris* antigen--stimulated MLN cells. (c) Total serum IgE antibody titers measured by ELISA. (d) Periodic acid--Schiff/Alcian blue--stained colon sections of intestine tissue from naive or infected WT or *Il17rb^−/−^* mice ± MPP^type2^ cells. N, naive (inset). Bars, 100 µm. (e) Goblet cell counts from d. (f) Worm burdens from *T. muris*--infected mice were assessed at day 21 after infection. Data in b--f are representative of two independent experiments (WT naive, *n* = 2--3; WT INF, *n* = 6--8; *Il17rb^−/−^* naive, *n* = 2--3; *Il17rb^−/−^* INF, *n* = 6--7; *Il17rb^−/−^* INF + MPP^type2^ cells, *n* = 6). \*, P \< 0.05; \*\*\*, P \< 0.001. IFN-γ production between *Il17rb^−/−^* INF and *Il17rb^−/−^* INF + MPP^type2^ cells, P = 0.068. Error bars indicate SEM.](JEM_20122332_Fig8){#fig8}

To test whether MPP^type2^ cells could promote protective Th2 cell--dependent immunity in the context of helminth infection, IL-25--elicited MPP^type2^ cells were sort-purified and adoptively transferred into *Il17rb^−/−^* mice that are normally susceptible to the intestinal helminth parasite *T. muris*. Protective anti-helminth immune responses were assessed on day 21 after infection. As expected, based on our previous study ([@bib32]), *T. muris*--infected *Il17rb^−/−^* mice exhibited heightened antigen-specific IFN-γ responses ([Fig. 8 b](#fig8){ref-type="fig"}), did not exhibit goblet cell hyperplasia ([Fig. 8, d and e](#fig8){ref-type="fig"}), and were unable to successfully clear infection ([Fig. 8 f](#fig8){ref-type="fig"}). In contrast, *T. muris*--infected *Il17rb^−/−^* mice that received adoptively transferred MPP^type2^ cells displayed decreased antigen-specific IFN-γ responses ([Fig. 8 b](#fig8){ref-type="fig"}), increased levels of total serum IgE ([Fig. 8 c](#fig8){ref-type="fig"}), and increased goblet cell hyperplasia ([Fig. 8, d and e](#fig8){ref-type="fig"}). Moreover, adoptive transfer of IL-25--elicited MPP^type2^ cells partially restored protective immunity in normally susceptible *Il17rb^−/−^* mice ([Fig. 8 f](#fig8){ref-type="fig"}). Collectively, these data demonstrate that MPP^type2^ cells are sufficient to partially restore Th2 cytokine responses and protective immunity in vivo.

DISCUSSION
==========

Although ILC2 and MPP^type2^ cell responses can be elicited by IL-33 and IL-25 and promote type 2 inflammation, the functional potential and relationship between these cell populations has remained unclear ([@bib28]; [@bib30]; [@bib36]; [@bib41]). In this study, we demonstrate that although IL-33 predominantly elicits ILC2 responses, IL-25 simultaneously elicits phenotypically and functionally distinct ILC2 and MPP^type2^ cell populations at multiple tissue sites. MPP^type2^ cells were distinguished from ILC2 by lack of surface expression of T1/ST2, IL-7Rα, CD90, and CD25, their genome-wide transcriptional profile, their multipotent potential, and their developmental dependence on Id2. Furthermore, IL-25--induced MPP^type2^ cells could promote Th2 cytokine--associated inflammation and Th2 cell--dependent immunity to helminth infection in mice in which the endogenous ILC2 response had been depleted.

Recent studies have reported differential induction of ILC2 responses by IL-33 and IL-25 ([@bib5]), suggesting that these cytokines promote type 2 cytokine--dependent inflammation through distinct innate immune mechanisms. Consistent with this, we found that IL-33 predominantly elicited ILC2 responses of greater magnitude to those observed after administration of IL-25. Notably, IL-33 also elicited a small population of MPP^type2^ cells despite their lack of IL-33 receptor expression. The IL-33--elicited MPP^type2^ cells were independent of IL-25 signaling, suggesting that this response may be regulated via alternate pathways such as IL-33--dependent induction of other hematopoietic growth factors including SCF, GM-CSF, or IL-3. However, future studies will be required to address this hypothesis. In contrast to IL-33, although IL-25 promotes modest ILC2 responses, IL-25 simultaneously elicits MPP^type2^ cells at multiple tissue sites. MPP^type2^ cells exhibited remarkable differences compared with ILC2 in their genome-wide transcriptional profile, multipotent potential, and Id2 dependence. Furthermore, the finding that IL-25--induced MPP^type2^ cells could promote type 2 cytokine--dependent inflammation in mice depleted of endogenous ILC2s identifies MPP^type2^ cells, independent of ILC2, as a critical innate cellular component in the development of Th2 cytokine--mediated inflammation at mucosal surfaces.

MPP^type2^ cells possess the potential to differentiate into multiple innate cell populations such as macrophages and mast cells and basophils capable of producing IL-4 and IL-13, thus implicating extramedullary hematopoiesis (EMH) as a mechanism through which IL-25 can promote type 2 immune responses. It is likely that MPP^type2^ cells and their progeny act cooperatively with other immune cell populations (including ILC2, granulocytes, macrophages, and/or T cells) to promote Th2 cytokine--associated immune responses and that immune cell populations might regulate the development and lineage potential of MPP^type2^ cells. However, additional studies will be required to further define the cellular interactions, mediators, and signaling pathways that regulate these processes.

Although we found that MPP^type2^ cells differed from ILC2 in their dependence on Id2, whether MPP^type2^ cells require other transcription factors necessary for the development of ILC2 such as RORα, GATA3, or TCF1 remains to be tested. Of note, our current data demonstrate that IL-25 promotes MPP^type2^ cell responses and type 2 inflammation in the absence of ILC2. However, [@bib10] and [@bib51] demonstrated that RORα is necessary for the IL-25--mediated induction of type 2 inflammation. Although these studies identified a role for RORα in the development of ILC2 responses, they did not investigate MPP^type2^ cell responses in RORα-deficient mice. Given both of these findings, it is possible that MPP^type2^ cells are themselves dependent on RORα. However, additional studies will be required to further characterize the molecular pathways involved in the development of IL-25--elicited MPP^type2^ cell responses.

Consistent with our functional analyses, PCA demonstrated that IL-25--elicited MPP^type2^ cells were more similar to BM-GMPs than to ILC2 or ILC3 populations. The significance of this finding is highlighted by reports of HSC mobilization out of the BM in response to microbial signals ([@bib29]; [@bib22]), where it is hypothesized that HSCs act as sentinels and contribute to immunosurveillance ([@bib22]). A recent study has also demonstrated that EMH is a key pathway in the IFN-dependent pathogenesis of IL-23--mediated colitis ([@bib9]). Collectively, these studies implicate EMH as an evolutionarily conserved mechanism of innate immunity that can direct the scope and intensity of adaptive immune responses in the context of infection and chronic inflammation.

The recent identification of CD34^pos^ progenitor-like cells in human asthmatic patients that share some similarities to IL-25--elicited MPP^type2^ cells including localization in peripheral tissues and responsiveness to Th2-associated cytokines ([@bib3]; [@bib41]) provokes the hypothesis that the IL-25--EMH--Th2 axis might also function in human disease. In support of this, increased expression of IL-25 and IL-25R has been reported in lung tissue of asthmatic patients ([@bib20]). Although human homologues of MPP^type2^ cells have yet to be identified, these data implicate IL-25--dependent EMH as a mechanism that influences the development of type 2 cytokine--dependent inflammation both in mice and humans.

TSLP, IL-33, and IL-25 are commonly coexpressed in epithelial cells and have multiple distinct cellular targets in vivo, including effects on mast cells, basophils, eosinophils, DC, macrophages, and T cells ([@bib21]; [@bib27]; [@bib38]; [@bib2]; [@bib13]; [@bib20]; [@bib39]; [@bib14]; [@bib35]; [@bib54]; [@bib43]). However, the apparent differences between the innate immune pathways elicited by TSLP, IL-33, and IL-25 suggest that epithelial cell--derived cytokines from different cytokine families regulate distinct modules of innate immune responses. For instance, whereas the IL-7--like cytokine TSLP has been shown to regulate DC and basophil responses ([@bib35]; [@bib49]; [@bib43]) and the IL-1 family member IL-33 promotes type 2 inflammation through IL-5 and IL-13 production from ILC2 ([@bib28]; [@bib25]; [@bib52]; [@bib51]), the IL-17 family member IL-25 is capable of promoting type 2 inflammation through the induction of a progenitor cell population that promotes EMH and subsequent IL-4 production. Consistent with the effects of IL-25 on progenitor cells that can promote monocyte and granulocyte responses, IL-17A, another member of the IL-17 cytokine family, promotes the expansion of other myeloid lineages ([@bib42]), indicating that promotion of granulopoiesis may be a characteristic of multiple IL-17 family members.

Despite the distinct cellular targets of IL-25, IL-33, and TSLP, this triad of epithelial cell--derived cytokines also exhibits a high degree of cross-regulation. Recent studies have shown that although not necessary for ILC2 development ([@bib12]), TSLP can synergize with IL-33, resulting in greater cytokine production from ILC2 ([@bib10]; [@bib24]). In addition, ILC2 populations in the skin have recently been identified and found to be dependent on TSLP--TSLPR interactions ([@bib16]), indicating that TSLP can directly influence ILC2 responses. However, although TSLP--TSLPR interactions were not required for the IL-25--mediated induction of MPP^type2^ cells responses in vivo, MPP^type2^ cells did express the TSLPRα chain (unpublished data). This suggests that similar to ILC2, TSLP might regulate MPP^type2^ cell responses; however, the role TSLP plays in MPP^type2^ cell biology remains unknown and warrants further investigation.

The coordinated expression of TSLP, IL-25, and IL-33 by epithelial cells in response to diverse allergens or helminth infections and interactions between these epithelial cell--derived cytokines may represent a mechanism by which epithelial cells can simultaneously induce multiple modules of the innate immune response that promote Th2 cell--dependent immunity, inflammation, and tissue repair by inducing distinct modules of the innate immune response ([@bib40]; [@bib54]; [@bib19]; [@bib31]; [@bib46]; [@bib26]; [@bib37]). Although the identification of these previously unrecognized innate immune cell populations provides new insights into the cellular mechanisms through which CD4^pos^ Th2 cell--dependent cytokine responses are initiated and regulated, the finding that MPP^type2^ cells represent a distinct population from ILC2 highlights the need for further investigation into the identity, function, and cell lineage relationships between MPP^type2^ cells, ILC2, and other progenitor-like cell populations. Understanding these relationships in the steady-state and in the context of infectious or inflammatory diseases may help establish novel therapeutic approaches for the treatment of helminth infections and allergic diseases in humans.

MATERIALS AND METHODS
=====================

### Mice.

WT BALB/c and WT C57BL/6 and *Rag1^−/−^* mice were obtained from Jackson Laboratory, and C57BL/6 Ly5.2/Cr (CD45.1) mice were obtained from the National Cancer Institute. C57BL/6 WT and C57BL/6 *Il33^−/−^* mice were from Taconic and were provided by D.E. Smith (Amgen). C57BL/6 WT and C57BL/6 *Il17rb^−/−^* mice (Charles River) were provided by A.L. Budelsky (Amgen). Animals were bred and housed in specific pathogen--free conditions at the University of Pennsylvania. All experiments were performed under Institutional Animal Care and Use Committee (IACUC)--approved protocols and in accordance with the guidelines of the IACUC of the University of Pennsylvania. All experiments were performed with age-, gender-, and genetically matched mice between the ages of 4 and 12 wk. Mice were treated i.p. with PBS, 0.3 µg of recombinant IL-25 (endotoxin level: 0.029 EU/ml; R&D Systems), or 0.3 µg of recombinant IL-33 (endotoxin level: 0.0285 EU/ml; eBioscience) daily for 2, 4, or 7 d. For anti-T1/ST2 antibody--mediated blockade, mice were treated i.p. with 0.25 mg/day of control IgG or anti-T1/ST2 (from D.E. Smith) on days −3, −1, 0, 2, and 4. For anti-CD90 antibody--mediated blockade, mice were treated i.p. with 0.3 mg/day of control IgG isotype (Iso.) or anti-CD90 (30H12; Bio X Cell) every 2 d beginning on day −3.

### BM chimera generation.

For all BM chimeras, BM was harvested from the tibia and femur and depleted of TCRβ^pos^, Thy1^pos^ cells or CD5^pos^ and B220^pos^ by magnetic beads (Miltenyi Biotec). For WT BM chimeras, purified donor cells (CD45.2) were injected i.v. into lethally irradiated (900 rad) recipient mice (CD45.1) through retroorbital injections. For *Id2*-deficient BM chimeras, purified donor cells (CD45.1.2^pos^) were injected i.v. into lethally irradiated (900 rad) recipient mice (CD45.2^pos^) through retroorbital injections. All *Id2*-deficient BM chimeras used were either second or third generation from fetal liver chimeras ([@bib6]). Generation of Id2-deficient mice and fetal liver chimeras has been described previously ([@bib6]). All other chimeras used were first generation. Reconstitution was allowed to proceed for 8 wk after transplant in all chimeras, and mice were maintained on antibiotics (1%) in the drinking water for 2 wk after transplant (Hi-Tech Pharmacal).

### Flow cytometry and cell sorting.

MLNs were separated from the mesentery, homogenized by passing through a 70-µm nylon mesh filter, and stained with anti--mouse fluorochrome-conjugated mAbs against CD3*ε*, CD4, CD8α, TCRβ, CD19, CD11b, CD11c, NK1.1, Fc*ε*RIα, c-kit, Sca-1, CD127 (IL-7Rα), CD90, CD25, and CD45.2 (eBioscience and BD). T1/ST2 staining was performed using T1/ST2 biotinylated mAb (MD Biosciences) and eFluor 450--conjugated streptavidin (eBioscience). Cells were run on an LSR II using DiVa software (BD) and analyzed with FlowJo software (version 9.4.11; Tree Star). For cell sorting, MLNs from IL-25--treated mice were isolated and stained with 1 µg/ml DAPI (Molecular Probes) as described above, and live (DAPI^neg^) MPP^type2^ cells (Lin^neg^ T1/ST2^neg^ IL-7Rα^neg^ CD90^neg^ CD25^neg^ c-kit^pos^), ILC2 cell populations (Lin^neg^ T1/ST2^pos^ IL-7Rα^pos^), and BM-GMP (Lin^neg^ Sca1^neg^ c-kit^pos^ CD34^pos^ CD16/32^pos^) were sorted using a FACSAria II (BD).

### Adoptive transfers and helminth infections.

For intradermal injections, 2 × 10^4^ FACS-purified IL-25--elicited MPP^type2^ cells were suspended in 50 µl PBS and injected intradermally into naive C57BL/6 WT mice. At day 5 after injection, skin-draining LNs were collected and polyclonally stimulated with 1 µg/ml each of αCD3 and αCD28 (eBioscience). After 48 h, cell-free supernatants were assessed for cytokine production by sandwich ELISA (eBioscience). For helminth infections, WT and *Il17rb^−/−^* mice (Charles River) were infected with 250 embryonated *T. muris* eggs via oral gavage. *T. muris*--infected *Il17rb^−/−^* mice were left untreated or given 7 × 10^4^ to 2 × 10^5^ FACS-purified IL-25--elicited MPP^type2^ cells at days 10, 12, 14, 16, and 18 after infection. Worm counts were performed at day 21 after infection. MLN cells were collected at necropsy and plated with 50 µg/ml 4h *T. muris* antigen as previously described ([@bib32]). After 48 h, cell-free supernatants were assessed for cytokine production by sandwich ELISA (eBioscience). Total serum IgE was measured using the OptEIA IgE ELISA kit (BD) according to the manufacturer's instructions.

### Microarray gene expression profiling and GSEA.

IL-25--elicited MPP^type2^ cells (Lin^neg^ T1/ST2^neg^ IL-7Rα^neg^ CD90^neg^ CD25^neg^ c-kit^pos^) were FACS purified from the MLNs and PECs of C57BL/6 mice, and BM-GMP (Lin^neg^ Sca1^neg^ c-kit^pos^ CD34^pos^ CD16/32^pos^) were sorted from the BM of naive C57BL/6 mice. Lineage markers included CD3*ε*, CD4, CD8α, CD19, CD11b, CD11c, and NK1.1. Three biological replicates were collected, each consisting of 50,000--70,000 cells. mRNA was isolated, amplified, and hybridized to the Mouse Gene 1.0ST GeneChip (Affymetrix). Using the ClassNeighbors function in GenePattern, differentially expressed genes (fold change greater than two, P \< 0.05) were identified. GSEA of gene expression profiles from each biological group was performed (Broad Institute). All microarray datasets were batch-corrected using the ComBat ([@bib15]) R script to normalize differences between samples caused by Affymetrix Chip. PCA ([@bib8]) and Euclidean distance measurements were performed using R (R Core Team), and hierarchical clustering analysis was performed using the unweighted pair group method with arithmetic mean (UPGMA) algorithm.

### In vitro differentiation assays.

Cell populations (MPP^type2^ cells or ILC2) were FACS purified as described above, seeded into 96-well flat bottom TC plates (Falcon; BD), and incubated in the presence of 50 ng/ml SCF (R&D Systems) and 10 ng/ml IL-3 (R&D Systems) or 50 ng/ml IL-33 (R&D Systems) for 8 d. Cytokines and culture media were replenished at days 3 and 6 after culture. After in vitro culture, progeny were assessed for expression of lineage-associated markers CD11b, Fc*ε*RIα, c-kit, T1/ST2, IL-7Rα (CD127), and CD90 by flow cytometry as described above. Cell-free supernatants were assessed for IL-4, IL-5, and IL-13 cytokine production by standard sandwich ELISA (eBioscience). Limits of detection are as follows: IL-4, 4.39 pg/ml; IL-5, 10 pg/ml; and IL-13, 8 pg/ml.

### Histology.

Lung and small intestinal tissues were fixed in 4% (vol/vol) paraformaldehyde and embedded in paraffin wax. 4-µm sections were stained with periodic acid--Schiff/Alcian blue.

### Real-time RT-PCR.

RNA from intestinal tissues of mice was isolated by TRIzol extraction (Invitrogen). Whole tissues were homogenized with a tissue homogenizer (TissueLyzer; QIAGEN), and cDNA was prepared with SuperScript reverse transcription (Invitrogen). Quantitative real-time PCR analysis used commercial QuantiTect primer sets for *Il4*, *Il5*, *Il13* (QIAGEN), and SYBR Green chemistry (Applied Biosystems). All reactions were run on an ABI 7500 Fast Real-Time PCR System (Applied Biosystems). Target genes were normalized for endogenous β-actin levels, and relative quantification of samples was compared with controls.

### Statistical analysis.

Representative plots for each sample group are shown. Statistical significance for total cell numbers was determined by two-tailed Student's *t* test using means ± SEM for individual groups. Results were considered significant at P \< 0.05.
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